Please login to the form below

Not currently logged in
Email:
Password:

salmeterol

This page shows the latest salmeterol news and features for those working in and with pharma, biotech and healthcare.

GSK’s Advair Diskus faces first generic in US

GSK’s Advair Diskus faces first generic in US

Teva won approval for its AirDuo product last year in the US, providing the same active ingredients as Advair but with a lower dose of salmeterol which means it is not

Latest news

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    of patent protection for COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol), even though competition in the US has been delayed by stringent FDA requirements for low-cost generics that have delayed

  • FDA hands GSK a reprieve by blocking Novartis generic FDA hands GSK a reprieve by blocking Novartis generic

    All three generics have been flummoxed by the complexity of Advair (salmeterol and fluticasone propionate) and the difficulty of showing sufficient equivalence with the Diskus dry powder inhaler used in the ... Teva won approval for its AirDuo product

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    vaccine Shingrix and recently-approved triple therapy for chronic obstructive pulmonary disorder (COPD) Trelegy - as it faces the imminent threat of generic competition to its big-selling respiratory drug Advair (salmeterol

More from news
Approximately 1 fully matching, plus 85 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics